Sign in
Taking people in United StatesPhase 2

Zinc supplements at different daily doses in people with sickle cell disease

Compares 25 mg/day and 40 mg/day zinc in people with sickle cell disease.

Key facts

Who runs it
University of California, San Francisco
Where
Cincinnati, Durham, Houston, Oakland, and Philadelphia, United StatesSee the 6 sites
Trial code
Registry title
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
Status
Recruiting
Phase
Phase 2
People taking part
34 people, planned
Started
14 Feb 2026
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • 25 mg/day zinc
  • 40 mg/day zinc
Record updated
13 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 15 to 40 with sickle cell disease (SCD-SS or SCD-S Beta zero Thalassemia) who are in a steady state. It tests two daily doses of zinc.

Age
15 to 40 years
Sex
Men and women can join.
Disease stage
Sickle cell disease of the type SCD-SS or SCD-S Beta zero Thalassemia, in steady state (at least 2 weeks after a pain crisis).
Earlier treatment
People who take a supplement with zinc must be able and willing to stop it for 3 months before the study starts.
Biomarker or test result
25-Hydroxy Vitamin D must not be below 20 ng/mL.

Main reasons for not taking part

  • Taking a zinc supplement and unable or unwilling to stop it for 3 months before the study
  • 25-Hydroxy Vitamin D below 20 ng/mL
  • Regular blood transfusions (more than 8 per year) together with iron overload
  • Unable to swallow pills or take a daily supplement as instructed
  • Taking part in another investigational drug trial or having chronic kidney disease (eGFR below 30 mL/min/1.73m2)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age: ≥ 15.0 to ≤ 40.0 years
  • Diagnosis: SCD-SS or SCD-S Beta zero Thalassemia, in steady state (defined as a minimum of 2 weeks days following pain crisis)
  • Male or Female

Who cannot take part

  • Taking any supplement containing zinc and unable/willing to stop for 3 months prior to study start
  • Currently participating in another investigational drug trial
  • On chronic transfusion therapy (defined as >8 Transfusions/year) and iron overloaded (defined as liver iron concentration > 7 mg/g OR average serum ferritin >4000 ug/L)
  • Prior diagnosis of chronic kidney disease (eGFR < 30 mL/min/1.73m2)
  • 25-Hydroxy Vitamin D < 20 ng/mL
  • Unable swallow pills or take daily supplement as instructed

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 15 and 40 years old?

Where in United States

  • Cincinnati Children's HospitalCincinnati, United StatesContact: Amy ShovaNot yet recruiting
  • Duke University Medical CenterDurham, United StatesContact: Rania MohamedNot yet recruiting
  • Baylor College of MedicineHouston, United StatesContact: Batha TariqNot yet recruiting
  • UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Ellen Fung, PhDTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Jemimah FrempongNot yet recruiting
  • Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Prasanna VardhanNot yet recruiting

About the trial

What the trial wants to find out

The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover? Participants will be recruited from 6 American Society Hematology Research Collaborative SCD Centers. Eligible SCD subjects will be invited to participate in the 16-week study, involving 2 baseline blood draws 4 weeks apart, followed by a 12-week zinc intervention. The findings from this study will be used to determine the dosage of zinc to be used in a larger, future study on the long term impact of zinc supplementation on bone health in SCD-SS.

The 2 groups in the trial

  • Dose 1: Zinc 25 mg/dayTreatment being tested

    25 mg of zinc as zinc gluconate taken orally once a day

    Treatment: 25 mg/day zinc

  • Dose 2: Zinc 40 mg/dayTreatment being tested

    40 mg of zinc as zinc gluconate taken orally once a day

    Treatment: 40 mg/day zinc

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
Plain-language title
Zinc supplements at different daily doses in people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06260891, who can take part
Record updated
13 March 2026